Strumento inattivo

Altre lingue PDI, Inc. Nasdaq

Azioni

US69329V1008

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

04/06	Interpace Diagnostics annuncia nuovi dati che analizzano lo squilibrio degli alleli delle ripetizioni brevi tandem per il rilevamento del cancro al pancreas, pubblicati come abstract ASCO 2024	CI
09/05	Interpace Biosciences, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract	04/06
Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract	04/06
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	09/05
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	07/03
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12/12
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	16/11
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	08/11
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	27/10/23
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	09/08/23
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	02/08/23
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	10/07/23
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PDI, Inc. Nasdaq

Azioni

US69329V1008

Altre lingue

Filtri